Biochemical Mechanism of Nitroglycerin Action and Tolerance: Is This Old Mystery Solved?

Annual Review of Pharmacology and Toxicology

Volumn 44, Issue , 2004, Pages 67-85

  Fung, Ho Leung ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bioactivation; Metabolism; Oxidative stress; Protein oxidation; Thionitrate

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2; ALPHA TOCOPHEROL; ANTIOXIDANT; ARGININE; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORAL HYDRATE; CYANAMIDE; CYSTEINE; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUTATHIONE; GLUTATHIONE TRANSFERASE; GLYCERYL TRINITRATE; HYDRALAZINE; NITRATE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITOR; SUPEROXIDE; THIOL DERIVATIVE; VASODILATOR AGENT;

DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; VASODILATATION;

CORONARY VESSELS; DRUG TOLERANCE; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; NITROGLYCERIN; OXIDATIVE STRESS; SUPEROXIDES; VASODILATOR AGENTS;

EID: 1342281276     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.44.101802.121646     Document Type: Review

References (83)

1. Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. 1996. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 18:301-4
2. Wang EQ, Soda DM, Fung HL. 2001. Nitroglycerin-induced relaxation of anorectal smooth muscle: evidence for apparent lack of tolerance development in the anaesthetized rat. Br. J. Pharmacol. 134:418-24
3. Lauretti GR, Perez MV, Reis MP, Pereira NL. 2002. Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. J. Clin. Anesth. 14:83-86
4. Chung SJ, Fung HL. 1990. Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J. Pharmacol. Exp. Ther. 253:614-19
5. Bennett BM, McDonald BJ, Nigam R, Simon WC. 1994. Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends Pharmacol. Sci. 15:245-49
6. Stewart DD. 1888. Remarkable tolerance to nitroglycerine. Polyclinic 6:43
7. Packer M. 1990. What causes tolerance to nitroglycerin? The 100 year old mystery continues. J. Am. Coll. Cardiol. 16:932-35
8. Healy M. 2002. Mystery of nitroglycerin cracked. USA Today, June 4
9. Chen Z, Zhang J, Stamler JS. 2002. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Natl. Acad. Sci. USA 99:8306-11
10. Gori T, Parker JD. 2002. Nitrate tolerance: a unifying hypothesis. Circulation 106:2510-13
11. Munzel T. 2001. Does nitroglycerin therapy hit the endothelium? J. Am. Coll. Cardiol. 38:1102-5
12. Fung HL, Bauer JA. 1994. Mechanisms of nitrate tolerance. Cardiovasc. Drugs Ther. 8:489-99
13. Parker JD, Parker JO. 1998. Nitrate therapy for stable angina pectoris. N. Engl. J. Med. 338:520-31
14. Fung HL, Poliszczuk R. 1986. Nitrosothiol and nitrate tolerance. Z. Kardiol. 75:25-27
15. Slack CJ, McLaughlin BE, Brien JF, Marks GS, Nakatsu K. 1989. Biotransformation of glyceryl trinitrate and isosorbide dinitrate in vascular smooth muscle made tolerant to organic nitrates. Can. J. Physiol. Pharmacol. 67:1381-85
16. Chung SJ, Fung HL. 1993. Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production. Probes with inhibitors and tolerance development. Biochem. Pharmacol. 45:157-63
17. Ignarro LJ. 2002. After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc. Natl. Acad. Sci. USA 99:7816-17
18. Chong S, Fung HL. 1991. Biochemical and pharmacological interactions between nitroglycerin and thiols. Effects of thiol structure on nitric oxide generation and tolerance reversal. Biochem. Pharmacol. 42:1433-39
19. Tseng CM, Tabrizi-Fard MA, Fung HL. 2000. Differential sensitivity among nitric oxide donors toward ODQ-mediated inhibition of vascular relaxation. J. Pharmacol. Exp. Ther. 292:737-42
20. Yeates RA, Laufen H, Leitold M. 1985. The reaction between organic nitrates and sulfhydryl compounds. A possible model system for the activation of organic nitrates. Mol. Pharmacol. 28:555-59
21. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, et al. 1981. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. 218:739-49
22. Balazy M, Kaminski PM, Mao K, Tan J, Wolin MS. 1998. S-Nitroglutathione, a product of the reaction between peroxynitrite and glutathione that generates nitric oxide. J. Biol. Chem. 273:32009-15
23. Kowaluk EA, Chung SJ, Fung HL. 1993. Nitrite ion is not an active intermediate in the vascular metabolism of organic nitrates and organic nitrites to nitric oxide. Drug. Metab. Dispos. 21:967-69
24. Artz JD, Yang K, Lock J, Sanchez C, Bennett BM, Thatcher GRJ. 1996. Reactivity of thionitrate esters: putative intermediates in nitrovasodilator activity. Chem. Commun. 8:927-28
25. Fung HL. 1993. Clinical pharmacology of organic nitrates. Am. J. Cardiol. Cell Physiol. 72:C9-13
26. MacAllister RJ. 2000. Arginine and nitrate tolerance. Br. J. Pharmacol. 130:209-10
27. Needleman P, Johnson EM Jr. 1973. Mechanism of tolerance development to organic nitrates. J. Pharmacol. Exp. Ther. 184:709-15
28. Olivari MT, Carlyle PF, Levine TB, Cohn JN. 1983. Hemodynamic and hormonal response to transdermal nitroglycerin in normal subjects and in patients with congestive heart failure. J. Am. Coll. Cardiol. 2:872-78
29. Bauer JA, Fung HL. 1993. Effect of apparent elimination half-life on nitroglycerin-induced hemodynamic rebound in experimental heart failure. Pharm. Res. 10:1341-45
30. Lange RL, Reid MS, Tresch DD, Keelan MH, Bernhard VM, Coolidge G. 1972. Nonatheromatous ischemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation 46:666-78
31. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. 1987. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N. Engl. J. Med. 317:799-804
32. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. 1991. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 84:2336-45
33. Bauer JA, Fung HL. 1994. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm. Res. 11:816-23
34. Bauer JA, Balthasar JP, Fung HL. 1997. Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerin tolerance in experimental heart failure. Pharm. Res. 14:1140-45
35. Wang EQ, Lee WI, Brazeau D, Fung HL. 2002. cDNA microarray analysis of vascular gene expression after nitric oxide donor infusions in rats: implications for nitrate tolerance mechanisms. AAPS PharmSci. 4:E10
36. Pi XC, Yan C, Kim D, Chen JY, Berk BC. 2002. Differential expression of genes from nitrate-tolerant rat aorta. J. Vasc. Res. 39:304-10
37. Kim D, Rybalkin SD, Pi XC, Wang YN, Zhang CX, et al. 2001. Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104:2338-43
38. Fung HL, McNiff EF, Ruggirello D, Darke A, Thadani U, Parker JO. 1981. Kinetics of isosorbide dinitrate and relationships to pharmacological effects. Br. J. Clin. Pharmacol. 11:579-90
39. Thadani U, Fung HL, Darke AC, Parker JO. 1980. Oral isosorbide dinitrate in the treatment of angina pectoris. Dose-response relationship and duration of action during acute therapy. Circulation 62:491-502
40. Sage PR, de la Lande IS, Stafford I, Bennett CL, Phillipov G, et al. 2000. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation 102:2810-15
41. Laursen JB, Mulsch A, Boesgaard S, Mordvintcev P, Trautner S, et al. 1996. In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation 94:2241-47.
42. Lee WI, Fung HL. 2003. Mechanism-based partial inactivation of glutathione S-transferases by nitroglycerin: tyrosine nitration vs sulfhydryl oxidation. Nitric Oxide 8:103-10
43. Hinz B, Schroder H. 1998. Nitrate tolerance is specific for nitric acid esters and its recovery requires an intact protein synthesis. Biochem. Biophys. Res. Commun. 252:232-35
44. Parker JO, Farrell B, Lahey KA, Moe G. 1987. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N. Engl. J. Med. 316:1440-44
45. Artz JD, Schmidt B, McCracken JL, Marletta MA. 2002. Effects of nitroglycerin on soluble guanylate cyclase: implications for nitrate tolerance. J. Biol. Chem. 277:18253-56
46. Munzel T, Li H, Mollnau H, Hink U, Matheis E, et al. 2000. Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ. Res. 86:E7-12
47. Wang EQ, Lee WI, Fung HL. 2002. Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice. Br. J. Pharmacol. 135:299-302
48. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. 1995. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J. Clin. Invest. 95:187-94
49. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, et al. 1996. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J. Clin. Invest. 98:1465-70
50. Munzel T, Kurz S, Heitzer T, Harrison DG. 1996. New insights into mechanisms underlying nitrate tolerance. Am. J. Cardiol. Cell Physiol. 77:C24-30
51. Kowaluk EA, Poliszczuk R, Fung HL. 1987. Tolerance to relaxation in rat aorta: comparison of an S-nitrosothiol with nitroglycerin. Eur. J. Pharmacol. 144:379-83
52. Chirkov YY, Chirkova LP, Horowitz JD. 1997. Nitroglycerin tolerance at the platelet level in patients with angina pectoris. Am. J. Cardiol. 80:128-31
53. Bauer JA, Fung HL. 1991. Differential hemodynamic effects and tolerance properties of nitroglycerin and an S-nitrosothiol in experimental heart failure. J. Pharmacol. Exp. Ther. 256:249-54
54. Bauer JA, Nolan T, Fung HL. 1997. Vascular and hemodynamic differences between organic nitrates and nitrites. J. Pharmacol. Exp. Ther. 280:326-31
55. Feelisch M, Ostrowski J, Noack E. 1989. On the mechanism of NO release from sydnonimines. J. Cardiovasc. Pharmacol. 14:S13-22
56. Stewart DJ, Holtz J, Bassenge E. 1987. Long-term nitroglycerin treatment: effect on direct and endothelium-mediated large coronary artery dilation in conscious dogs. Circulation 75:847-56
57. Sutsch G, Kim JH, Bracht C, Kiowski W. 1997. Lack of cross-tolerance to short-term linsidomine in forearm resistance vessels and dorsal hand veins in subjects with nitroglycerin tolerance. Clin. Pharmacol. Ther. 62:538-45
58. Govantes C, Rodriguez-Martinez MA, Marin J. 1996. Vasodilator effect and tolerance induced by the nitrocompound SIN-1 in rabbit femoral artery. Methods Find. Exp. Clin. Pharmacol. 18:387-95
59. Bohyn M, Berkenboom G, Fontaine J. 1991. Effect of nitrate tolerance and dipyridamole on the response to SIN1 in the human isolated saphenous vein. Cardiovasc. Drugs Ther. 5:457-61
60. Ujiie K, Hogarth L, Danziger R, Drewett JG, Yuen PS, et al. 1994. Homologous and heterologous desensitization of a guanylyl cyclase-linked nitric oxide receptor in cultured rat medullary interstitial cells. J. Pharmacol. Exp. Ther. 270:761-67
61. Henry PJ, Horowitz JD, Louis WJ. 1990. Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity. J. Cardiovasc. Pharmacol. 15:365-70
62. Hinz B, Schroder H. 1998. Vitamin C attenuates nitrate tolerance independently of its antioxidant effect. FEBS Lett. 428:97-99
63. Laight DW, Carrier MJ, Anggard EE. 1997. Investigation of role for oxidant stress in vascular tolerance development to glyceryl trinitrate in vitro. Br. J. Pharmacol. 120:1477-82
64. Hussain AS, Brien JF, Marks GS, Nakatsu K. 1996. Superoxide does not inhibit glyceryl trinitrate-rabbit aortic strip-mediated relaxation of rabbit Taenia coli. Evidence against a role for nitric oxide itself as the smooth muscle active drug metabolite? Drug Metab. Dispos. 24:780-85
65. Csont T, Csonka C, Onody A, Gorbe A, Dux L, et al. 2002. Nitrate tolerance does not increase production of peroxynitrite in the heart. Am. J. Physiol. Heart Circ. Physiol. 283:H69-76
66. Hanspal IS, Magid KS, Webb DJ, Megson IL. 2002. The effect of oxidative stress on endothelium-dependent and nitric oxide donor-induced relaxation: implications for nitrate tolerance. Nitric Oxide 6:263-70
67. Keimer R, Stutzer FK, Tsikas D, Troost R, Gutzki FM, Frolich JC. 2003. Lack of oxidative stress during sustained therapy with isosorbide dinitrate and pentaerythrityl tetranitrate in healthy humans: a randomized, double-blind crossover study. J. Cardiovasc. Pharmacol. 41:284-92
68. Pieper GM, Langenstroer P, Siebeneich W. 1997. Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovasc. Res. 34:145-56
69. Laight DW, Kengatharan KM, Gopaul NK, Anggard EE, Carrier MJ. 1998. Investigation of oxidant stress and vasodepression to glyceryl trinitrate in the obese Zucker rat in vivo. Br. J. Pharmacol. 125:895-901
70. Wang EQ, Fung HL. 2002. Effects of obesity on the pharmacodynamics of nitroglycerin in conscious rats. AAPS PharmSci. 4:28
71. Kurz S, Hink U, Nickenig G, Borthayre AB, Harrison DG, Munzel T. 1999. Evidence for a causal role of the reninangiotensin system in nitrate tolerance. Circulation 99:3181-87
72. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, et al. 1998. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ. Res. 83:743-51
73. Parker JO, Parker JD. 1992. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am. J. Cardiol. 70:B93-97
74. Bachert EL. 1994. Nicorandil and nitrovasodilators: pharmacokinetic, pharmacodynamic and mechanistic aspects. PhD thesis. Univ. Buffalo, State Univ. New York. 214 pp.
75. Gori T, Mak SS, Kelly S, Parker JD. 2001. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans. J. Am. Coll. Cardiol. 38:1096-101
76. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, et al. 2002. Functional and biochemical analysis of endothelial (dys)function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation 105:1170-75
77. Abou-Mohamed G, Kaesemeyer WH, Caldwell RB, Caldwell RW. 2000. Role of L-arginine in the vascular actions and development of tolerance to nitroglycerin. Br. J. Pharmacol. 130:211-18
78. Parker JO, Parker JD, Caldwell RW, Farrell B, Kaesemeyer WH. 2002. The effect of supplemental L-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J. Am. Coll. Cardiol. 39:1199-203
79. Gruhn N, Boesgaard S, Andersen C, Aldershvile J. 2002. Nitroglycerin tolerance: different mechanisms in vascular segments with or without intact endothelial function. J. Cardiovasc. Pharmacol. 40:201-9
80. Booth BP, Nolan TD, Fung HL. 1997. Nitroglycerin-inhibited whole blood aggregation is partially mediated by calcitonin gene-related peptide-a neurogenic mechanism. Br. J. Pharmacol. 122:577-83
81. Booth BP, Tabrizi-Fard MA, Fung HL. 2000. Calcitonin gene-related peptide-dependent vascular relaxation of rat aorta. An additional mechanism for nitroglycerin. Biochem. Pharmacol. 59:1603-9
82. Booth BP, Fung HL. 1998. Regulation of in vivo whole blood aggregation in rats by calcitonin gene related peptide. Can. J. Physiol. Pharmacol. 76:811-13
83. Lee WI, Xu Y, Fung SM, Fung HL. 2003. eNOS-dependent vascular interaction between nitric oxide and calcitonin gene-related peptide in mice: gender selectivity and effects on blood aggregation. Regul. Peptides 110:115-22